VivoSeq
Other

Rejection

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Rejection is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting2 · 40%
Completed2 · 40%
Unknown status1 · 20%

Clinical Trials

Trial Activity

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection
Recruiting·UUniversity of Virginia·Phase 2·NCT07046910·60 enrolled
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
Completed·PPrice Vision Group·Phase 2·NCT01448213·264 enrolled
The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes
Unknown status·SSamsung Medical Center·N/A·NCT02664493·154 enrolled
Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT07134491·45 enrolled
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Completed·—·Phase 1/2·NCT01134510·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)